Takeda Pharmaceutical (TAK) Long-Term Deferred Tax (2017 - 2026)

Takeda Pharmaceutical's Long-Term Deferred Tax history runs 10 years deep, the most recent figure standing at $3.1 billion for Q1 2026.

• In Q1 2026, Long-Term Deferred Tax rose 28.02% year-over-year to $3.1 billion; the TTM figure through Mar 2026 stood at $3.1 billion (up 28.02% YoY), while the FY2026 annual figure was $3.2 billion, up 33.16% from the prior year.
• Long-Term Deferred Tax was $3.1 billion for Q1 2026 at Takeda Pharmaceutical, up from $2.8 billion in the prior quarter.
• In the past five years, Long-Term Deferred Tax ranged from a high of $3.1 billion in Q1 2022 to a low of $2.1 billion in Q4 2023.
• Historically, Long-Term Deferred Tax has averaged $2.7 billion across 5 years, with a median of $2.7 billion in 2024.
• The sharpest annual moves came in 2023 and 2026: Long-Term Deferred Tax dropped 18.55% in 2023, then climbed 28.02% in 2026.
• A 5-year view of Long-Term Deferred Tax shows it stood at $2.5 billion in 2022, then retreated by 15.78% to $2.1 billion in 2023, then rose by 15.52% to $2.5 billion in 2024, then climbed by 12.23% to $2.8 billion in 2025, then rose by 11.99% to $3.1 billion in 2026.
• The last three Long-Term Deferred Tax figures came in at $3.1 billion (Q1 2026), $2.8 billion (Q4 2025), and $2.6 billion (Q3 2025), per Business Quant data.